Published in Drug Des Devel Ther on November 13, 2013
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease | NCT01224106
A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease. | NCT00531804
Current Research Therapeutic Strategies for Alzheimer's Disease Treatment. Neural Plast (2016) 0.80
Neurologically Potent Molecules from Crataegus oxyacantha; Isolation, Anticholinesterase Inhibition, and Molecular Docking. Front Pharmacol (2017) 0.75
Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin (2017) 0.75
Antibody Therapeutics Targeting Aβ and Tau. Cold Spring Harb Perspect Med (2017) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Alzheimer's disease is a synaptic failure. Science (2002) 13.82
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci (2002) 5.01
2013 Alzheimer's disease facts and figures. Alzheimers Dement (2013) 4.75
Clearing the brain's amyloid cobwebs. Neuron (2001) 2.87
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol (2011) 2.75
Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci (2002) 2.42
Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol (2006) 2.25
Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J Neurochem (2004) 1.99
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement (2013) 1.98
Beta-amyloid monomers are neuroprotective. J Neurosci (2009) 1.87
The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem Soc Trans (2005) 1.84
Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J Neurosci (2008) 1.43
Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis (2012) 1.39
Abeta oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. J Neurosci (2007) 1.28
Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing! Age Ageing (2006) 1.24
Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific. J Neurosci (2012) 1.16
The role of the immune system in clearance of Abeta from the brain. Brain Pathol (2008) 1.14
Bapineuzumab. Expert Opin Biol Ther (2010) 1.12
Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production. Ann Neurol (2005) 1.05
Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol (2002) 1.04
Na+ -Ca2+ exchanger (NCX3) knock-out mice display an impairment in hippocampal long-term potentiation and spatial learning and memory. J Neurosci (2011) 1.03
Peptide inhibitors of beta amyloid aggregation. Curr Top Med Chem (2002) 0.99
A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease? Trends Pharmacol Sci (2005) 0.99
ACET is a highly potent and specific kainate receptor antagonist: characterisation and effects on hippocampal mossy fibre function. Neuropharmacology (2008) 0.97
Increased D-aspartate brain content rescues hippocampal age-related synaptic plasticity deterioration of mice. Neurobiol Aging (2010) 0.96
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors. J Med Chem (2005) 0.95
The γ-secretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 mice. J Alzheimers Dis (2011) 0.95
Increased levels of d-aspartate in the hippocampus enhance LTP but do not facilitate cognitive flexibility. Mol Cell Neurosci (2007) 0.95
A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro. Br J Pharmacol (2002) 0.94
Inflammation subverts hippocampal synaptic plasticity in experimental multiple sclerosis. PLoS One (2013) 0.93
Targeting synaptic dysfunction in Alzheimer's disease therapy. Mol Neurobiol (2012) 0.93
Huperzine A and tacrine attenuate beta-amyloid peptide-induced oxidative injury. J Neurosci Res (2000) 0.90
Persistent increase of D-aspartate in D-aspartate oxidase mutant mice induces a precocious hippocampal age-dependent synaptic plasticity and spatial memory decay. Neurobiol Aging (2009) 0.89
A novel compound RS-0466 reverses beta-amyloid-induced cytotoxicity through the Akt signaling pathway in vitro. Eur J Pharmacol (2002) 0.87
Age-related changes of hippocampal synaptic plasticity in AβPP-null mice are restored by NGF through p75NTR. J Alzheimers Dis (2013) 0.86
Huperzine A and donepezil protect rat pheochromocytoma cells against oxygen-glucose deprivation. Neurosci Lett (2001) 0.85
Solanezumab for Alzheimer's disease. Expert Opin Biol Ther (2011) 0.83
Cognitive impairment and dentate gyrus synaptic dysfunction in experimental parkinsonism. Biol Psychiatry (2013) 0.83
Huperzine B protects rat pheochromocytoma cells against oxygen-glucose deprivation-induced injury. Acta Pharmacol Sin (2002) 0.83
Proteolytic degradation of the amyloid beta-protein: the forgotten side of Alzheimer's disease. Curr Alzheimer Res (2006) 0.82
Antioxidant enzymatic activities in Alzheimer's disease: the relationship to acetylcholinesterase inhibitors. J Alzheimers Dis (2012) 0.80
Enhanced mGlu5-receptor dependent long-term depression at the Schaffer collateral-CA1 synapse of congenitally learned helpless rats. Neuropharmacology (2012) 0.79
Synaptic plasticity as a therapeutic target in the treatment of autism-related single-gene disorders. Curr Pharm Des (2013) 0.78
γ -Secretase Pharmacology: What Pharmacology Will Work for Alzheimer's Disease? Int J Alzheimers Dis (2013) 0.76
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) (2011) 2.72
Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci U S A (2005) 2.13
ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem (2005) 2.11
Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. Nat Med (2010) 2.10
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget (2012) 1.96
L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc Natl Acad Sci U S A (2013) 1.94
Beta-amyloid monomers are neuroprotective. J Neurosci (2009) 1.87
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
Propofol enhances memory formation via an interaction with the endocannabinoid system. Anesthesiology (2011) 1.76
Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA-induced dyskinesia. Nat Neurosci (2011) 1.74
Control of PKA stability and signalling by the RING ligase praja2. Nat Cell Biol (2011) 1.66
Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J Neurosci (2004) 1.66
Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci (2005) 1.57
GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget (2014) 1.56
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle (2009) 1.54
Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl) (2009) 1.50
In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. Cell Cycle (2011) 1.46
Vitamin D3: a helpful immuno-modulator. Immunology (2011) 1.46
Loss of striatal cannabinoid CB1 receptor function in attention-deficit / hyperactivity disorder mice with point-mutation of the dopamine transporter. Eur J Neurosci (2011) 1.45
Functional characterization of WNT7A signaling in PC12 cells: interaction with A FZD5 x LRP6 receptor complex and modulation by Dickkopf proteins. J Biol Chem (2003) 1.44
Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurosci (2006) 1.42
Akt as a therapeutic target in cancer. Expert Opin Ther Targets (2008) 1.41
Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J Neurosci (2003) 1.41
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol (2011) 1.40
Editorial. Curr Neuropharmacol (2006) 1.40
TGF-beta1 targets the GSK-3beta/beta-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. Pharmacol Res (2008) 1.40
Unilateral spatial neglect and alien limb phenomenon may be early features of Creutzfeldt-Jakob disease. Parkinsonism Relat Disord (2012) 1.39
The conditioned eyeblink reflex: a potential tool for the detection of cerebellar dysfunction in multiple sclerosis. Mult Scler (2011) 1.39
The dopamine-containing neuron: maestro or simple musician in the orchestra of addiction? Trends Pharmacol Sci (2003) 1.39
Metabotropic glutamate 1 receptor: current concepts and perspectives. Pharmacol Rev (2008) 1.38
The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection. J Neurosci (2007) 1.38
Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology (2005) 1.36
Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is required for the development of ischemic neuronal death. J Neurosci (2005) 1.32
Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res (2008) 1.26
Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. Neuropharmacology (2012) 1.21
Involvement of transient receptor potential-like channels in responses to mGluR-I activation in midbrain dopamine neurons. Eur J Neurosci (2003) 1.19
The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle (2010) 1.18
The Wnt pathway, cell-cycle activation and beta-amyloid: novel therapeutic strategies in Alzheimer's disease? Trends Pharmacol Sci (2003) 1.17
Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle (2011) 1.17
Depression and Alzheimer's disease: neurobiological links and common pharmacological targets. Eur J Pharmacol (2009) 1.16
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget (2011) 1.16
Emerging MEK inhibitors. Expert Opin Emerg Drugs (2010) 1.16
Induction of the Wnt inhibitor, Dickkopf-1, is associated with neurodegeneration related to temporal lobe epilepsy. Epilepsia (2007) 1.14
N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology (2006) 1.14
Microbial targeting of 99mTc-labeled recombinant human beta-defensin-3 in an animal model of infection: a feasibility pilot study. J Nucl Med (2009) 1.13
Induction of the Wnt antagonist, Dickkopf-1, contributes to the development of neuronal death in models of brain focal ischemia. J Cereb Blood Flow Metab (2008) 1.13
A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal gabaergic Transmission. Neuropsychopharmacology (2004) 1.13
Activation of TRPV1 in the VTA excites dopaminergic neurons and increases chemical- and noxious-induced dopamine release in the nucleus accumbens. Neuropsychopharmacology (2005) 1.10
Role of aberrant striatal dopamine D1 receptor/cAMP/protein kinase A/DARPP32 signaling in the paradoxical calming effect of amphetamine. J Neurosci (2010) 1.10
Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo. Neuro Oncol (2005) 1.09
Prenatal restraint stress generates two distinct behavioral and neurochemical profiles in male and female rats. PLoS One (2008) 1.08
Resistance to TRAIL and how to surmount it. Immunol Res (2012) 1.08
Effects of epilepsy treatment on sleep architecture and daytime sleepiness: an evidence-based review of objective sleep metrics. Epilepsia (2014) 1.07
Pharmacological activation of mGlu4 metabotropic glutamate receptors inhibits the growth of medulloblastomas. J Neurosci (2006) 1.06
Advances in targeting signal transduction pathways. Oncotarget (2012) 1.06
Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus. J Cell Physiol (2008) 1.05
Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells. J Neurochem (2004) 1.05
The fat-induced satiety factor oleoylethanolamide suppresses feeding through central release of oxytocin. J Neurosci (2010) 1.04
TGF-beta 1 protects against Abeta-neurotoxicity via the phosphatidylinositol-3-kinase pathway. Neurobiol Dis (2008) 1.04
BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology (2012) 1.04
Temperature sensitivity of dopaminergic neurons of the substantia nigra pars compacta: involvement of transient receptor potential channels. J Neurophysiol (2005) 1.03
Pharmacological blockade of mGlu2/3 metabotropic glutamate receptors reduces cell proliferation in cultured human glioma cells. J Neurochem (2003) 1.03
Na+ -Ca2+ exchanger (NCX3) knock-out mice display an impairment in hippocampal long-term potentiation and spatial learning and memory. J Neurosci (2011) 1.03
Metabotropic glutamate receptors in glial cells. Neurochem Res (2008) 1.02
Metabotropic glutamate receptors in stem/progenitor cells. Neuropharmacology (2007) 1.01
Role of G protein-coupled receptor kinase 4 and beta-arrestin 1 in agonist-stimulated metabotropic glutamate receptor 1 internalization and activation of mitogen-activated protein kinases. J Biol Chem (2003) 1.01
Potential use of rapamycin in HIV infection. Br J Clin Pharmacol (2010) 1.00
Experience-induced Arc/Arg3.1 primes CA1 pyramidal neurons for metabotropic glutamate receptor-dependent long-term synaptic depression. Neuron (2013) 1.00
Metabotropic glutamate receptors and the control of chronic pain. Curr Opin Pharmacol (2011) 1.00
Inhibition of Wnt signaling, modulation of Tau phosphorylation and induction of neuronal cell death by DKK1. Neurobiol Dis (2006) 1.00
DNA polymerase-beta is expressed early in neurons of Alzheimer's disease brain and is loaded into DNA replication forks in neurons challenged with beta-amyloid. J Neurosci (2006) 0.99
Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J Neurosci (2004) 0.99
Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice. Neuropsychopharmacology (2011) 0.99
GISP binding to TSG101 increases GABA receptor stability by down-regulating ESCRT-mediated lysosomal degradation. J Neurochem (2008) 0.99
Group I metabotropic glutamate receptors: a role in neurodevelopmental disorders? Mol Neurobiol (2007) 0.99
Transcriptional regulation of type-2 metabotropic glutamate receptors: an epigenetic path to novel treatments for chronic pain. Trends Pharmacol Sci (2010) 0.99
Inhibition of the canonical Wnt signaling pathway by apolipoprotein E4 in PC12 cells. J Neurochem (2006) 0.98
Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity. J Neurosci (2002) 0.98
Interaction between ephrins/Eph receptors and excitatory amino acid receptors: possible relevance in the regulation of synaptic plasticity and in the pathophysiology of neuronal degeneration. J Neurochem (2006) 0.98
ACET is a highly potent and specific kainate receptor antagonist: characterisation and effects on hippocampal mossy fibre function. Neuropharmacology (2008) 0.97
Activation of group II metabotropic glutamate receptors promotes DNA demethylation in the mouse brain. Mol Pharmacol (2011) 0.97
Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells. Neoplasia (2010) 0.97
Insulin secretion is controlled by mGlu5 metabotropic glutamate receptors. Mol Pharmacol (2006) 0.96
MGluR5 mediates the interaction between late-LTP, network activity, and learning. PLoS One (2008) 0.96
Increased D-aspartate brain content rescues hippocampal age-related synaptic plasticity deterioration of mice. Neurobiol Aging (2010) 0.96
Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1. Mol Brain (2013) 0.96